• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[在犬颈总动脉血栓模型中使用组织型纤溶酶原激活剂和尿激酶进行局部纤溶的实验研究]

[An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].

作者信息

Kawakami K, Takahashi A, Yoshimoto T

机构信息

Division of Neurosurgery, Tohoku University School of Medicine, Sendai, Japan.

出版信息

No To Shinkei. 1990 Feb;42(2):193-201.

PMID:2113401
Abstract

Tissue-type plasminogen activator (t-PA) is thought to be a promising fibrinolytic agent because of its high affinity to fibrin without evidence of significant systemic fibrinolysis. The feasibility of t-PA and urokinase (UK) in local fibrinolytic therapy was investigated in a canine common carotid artery thrombus model. After the screening of coagulation-fibrinolytic activities, autologous blood clot was injected into the segment of intimal injured common carotid artery. The fibrinolytic agent was locally applied from the origin of the common carotid artery under temporary flow arrest with a double lumen balloon catheter. T-PA used in this study was produced by the cell culture technique of normal human cells. Its activity was-expressed by AK units (AKU), namely, the fibrinolytic area of the fibrin-agar plate induced by 10 AKU/ml of t-PA solution corresponds to that of 10 IU/ml of UK solution. The doses of t-PA required to produce angiographical recanalization were 600-1,200 AKU/kg (approximately 0.015-0.03 mg/kg) of t-PA, while 24,000 IU/kg was necessary for UK. In these doses, t-PA evoked no adverse effects on the plasma coagulation-fibrinolytic system, while UK produced significant decrease in plasma fibrinogen and alpha-2 plasmin inhibitor levels. Thus, t-PA may be considered to have higher fibrinolytic ability and lower adverse effect on the plasma coagulation-fibrinolytic system than UK. Local fibrinolytic therapy for acute cerebral infarction using t-PA is considered to be a promising intravascular therapeutic procedure with less systemic fibrinolytic complications such as hemorrhagic infarction.

摘要

组织型纤溶酶原激活剂(t-PA)因其对纤维蛋白具有高亲和力且无明显全身纤溶证据,被认为是一种很有前景的纤溶药物。在犬类颈总动脉血栓模型中研究了t-PA和尿激酶(UK)进行局部纤溶治疗的可行性。在筛选凝血-纤溶活性后,将自体血凝块注入内膜损伤的颈总动脉段。在使用双腔球囊导管暂时阻断血流的情况下,从颈总动脉起始处局部应用纤溶药物。本研究中使用的t-PA是通过正常人细胞的细胞培养技术生产的。其活性以AK单位(AKU)表示,即10 AKU/ml的t-PA溶液诱导的纤维蛋白-琼脂平板的纤溶面积与10 IU/ml的UK溶液的纤溶面积相当。血管造影再通所需的t-PA剂量为600 - 1200 AKU/kg(约0.015 - 0.03 mg/kg)的t-PA,而UK则需要24000 IU/kg。在这些剂量下,t-PA对血浆凝血-纤溶系统未产生不良影响,而UK则使血浆纤维蛋白原和α-2纤溶酶抑制剂水平显著降低。因此,与UK相比,t-PA可能被认为具有更高的纤溶能力且对血浆凝血-纤溶系统的不良影响更小。使用t-PA对急性脑梗死进行局部纤溶治疗被认为是一种很有前景的血管内治疗方法,其全身纤溶并发症如出血性梗死较少。

相似文献

1
[An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].[在犬颈总动脉血栓模型中使用组织型纤溶酶原激活剂和尿激酶进行局部纤溶的实验研究]
No To Shinkei. 1990 Feb;42(2):193-201.
2
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.急性缺血性心脏病患者的纤维蛋白溶解。特别提及组织型纤溶酶原激活剂治疗对纤维蛋白溶解、凝血和补体途径的全身影响。
Dan Med Bull. 1993 Sep;40(4):383-408.
3
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
4
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。
Thromb Haemost. 1986 Aug 20;56(1):35-9.
5
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.采用纤维蛋白和非纤维蛋白检测法测定人肿瘤组织及相邻正常组织中的纤溶酶原激活物含量。
Cancer Res. 1986 Apr;46(4 Pt 1):1788-94.
6
Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.纤维蛋白溶解的分子机制及其在纤维蛋白特异性溶栓治疗中的应用。
J Cell Biochem. 1987 Feb;33(2):77-86. doi: 10.1002/jcb.240330202.
7
A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
Blood Coagul Fibrinolysis. 1993 Aug;4(4):569-75.
8
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂(K2tu-PA:CGP 42935)的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.
9
Fibrin-specific thrombolytic agents.纤维蛋白特异性溶栓剂。
Schweiz Med Wochenschr. 1987 Nov 14;117(46):1791-8.
10
[New thrombolytic agents in myocardial infarction].[心肌梗死中的新型溶栓药物]
Arch Mal Coeur Vaiss. 1987 Nov;80(12):1785-91.